CELCUITY INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.76 USD | +0.03% |
|
-1.43% | +13.45% |
| May. 16 | Craig-Hallum Adjusts Price Target on Celcuity to $27 From $25, Assumes Buy Rating | MT |
| May. 16 | Celcuity Q1 Net Loss Widens; Shares Rise After Hours | MT |
Presentation Operator MessageOperator (Operator)Good day and welcome to the Celcuity Third Qua...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
16.76
USD
Average target price
28.96
USD
Spread / Average Target
+72.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.45% | 523M | |
| +9.63% | 115B | |
| +11.78% | 106B | |
| -2.97% | 21.96B | |
| -14.22% | 21.87B | |
| -5.29% | 19.21B | |
| -4.31% | 18.08B | |
| -38.29% | 17.71B | |
| +7.13% | 14.32B | |
| +35.79% | 12.42B |
- Stock Market
- Equities
- CELC Stock
- News Celcuity Inc.
- Transcript : Celcuity Inc., Q3 2022 Earnings Call, Nov 10, 2022